AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024 AmgenView Full coverage on Google News
Findings From Tezspire® (tezepelumab-ekko) Phase 2a COURSE COPD Study Phase 1 Study on AMG104/AZD8630 (Inhaled Anti-TSLP) in Moderate to Severe Asthma New TAVNEOS® (avacopan) Data in Adults With Severe Active ANCA-Associated Vasculitis With Lung Involvement THOUSAND OAKS, Calif. , May 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego . Thirteen abstracts supporting two approved medicines and one investigational treatment will be presented. "We look forward to presenting encouraging data from our Phase 2a COURSE trial in COPD with Tezspire and our Phase 1 investigational study of asthma with AMG104/AZD8630, an inhaled anti-TSLP therapy," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen . "Our efforts underscore Amgen 's commitment to pioneering new treatments for respiratory diseases with currently limited treatment options." Data from the COURSE trial will be presented within the Clinical Trials Symposium. COURSE was a proof-of-concept, Phase 2a study evaluating the safety and efficacy of Tezspire® (tezepelumab-ekko) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), irrespective of inflammatory drivers, blood eosinophil count (BEC), emphysema, chronic bronchitis and smoking status. Other research highlights include late-breaking data from the Phase 1 study of AMG104/AZD8630, an investigational inhaled anti-TSLP therapy being evaluated in patients with poorly controlled asthma, as well as a post-hoc analysis from the Phase 3 ADVOCATE trial, which assessed the efficacy and safety of TAVNEOS® (avacopan) in patients with severe active ANCA-associated vasculitis (GPA or MPA) with lung involvement. Abstracts and Presentation Times: TEZSPIRE Tezepelumab in Adults with Moderate to Very Severe Chronic…